WCG’s WIRB-Copernicus IRB, an industry leader in the ethical and regulatory human research oversight, announced a new program in support of the initiation of protocols associated with mitigating the global spread of coronavirus. WIRB-Copernicus IRB offers a prioritized review of clinical trial protocols for COVID-19 (coronavirus) prophylactic or therapeutic vaccines and therapeutic agents conducted under an investigational new drug (IND) application. In addition, the organization is waiving the initial protocol review fees for specific coronavirus research.
WIRB-Copernicus recently announced to all sponsors seeking to qualify the COVID-19, that protocol must be submitted before Sept. 1, 2020. Donald A. Deieso, Ph.D., Executive Chairman and CEO of WCG declared, “Time is of the essence. We need to support healthcare researchers in their efforts to discover effective medications and vaccines to treat and protect global citizens from this new coronavirus, COVID-19.” Deieso continued, “Our WCG staff want to put their skills to optimal use and play an active role in helping to address this global healthcare crisis. Through this IRB prioritization program, we can expedite the start-up of clinical trials for COVID-19 vaccines and therapies while maintaining the highest quality and ethical review standards.”
WCG Clinical Summary
One of the largest and prominent firms of its kind, WCG is a leading organization focused on a range of services and products helping research sponsors and sites to improve the quality and efficiency of clinical research. Comprised of two divisions—the industry’s first central IRB—WIRB Copernicus IRB and first clinical services organization (CSO)—WCG enables biopharma sponsors, CROs, and research institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protection.
Call to Action: Interested in taking advantage of the new program to accelerate the initiation of coronavirus protocols associated with mitigating the global spread of coronavirus? Contact Amy Hutnik at ahutnik@wcgclincalcom.Source: